TY - JOUR T1 - Prolonged oral corticosteroid therapy in allergic bronchopulmonary aspergillosis (ABPA) treatment does not increase pseudomonas aeruginosa risk JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.congress-2015.PA1300 VL - 46 IS - suppl 59 SP - PA1300 AU - Miguel Garcia Gonzalez AU - Karen McKay AU - Peter Cooper AU - Hiran Selvadurai AU - Dominic Fitzgerald AU - Paul D. Robinson Y1 - 2015/09/01 UR - http://erj.ersjournals.com/content/46/suppl_59/PA1300.abstract N2 - Background: Oral corticosteroids (OCS) are potent anti-inflammatory drugs with immunosuppressive effect. Chronic OCS use may increase the risk of bacterial infection. ABPA is a common Cystic Fibrosis (CF) complication recquiring high dose prolonged OCS treatmentAims: To investigate whether prolonged OCS treatment in CF ABPA subjects increases subsequent Pseudomonas aeruginosa (PsA) acquisitionMethods: Retrospective analysis. Cases of ABPA within a CF clinic between 2004-2010. Data excluded if chronic PsA colonisation occurred prior to ABPA diagnosis. PsA status was defined for each year of the 2 years immediately before to 2 years after ABPA diagnosis and classified as PsA-free, single isolation, intermittent (<3/year) or colonised (≥3/year or use of regular antiPsA therapy). Subjects were matched by sex and age to ABPA negative CF controls, without chronic PsA colonisation (case-control ratio 1:2)Results: 25 subjects with ABPA (clinic size: 250 patients) were identified: 42% female, mean (sd) age 8.8 (2.8) years. No baseline difference in lung function, genotype or rate of pancreatic insufficiency existed between ABPA subjects and controls. All subjects had ≥12 weeks of OCS + antifungal treatment as per centre protocol PsA status worsened in 8/25 (32%) of ABPA vs 8/50 (16%) control subjects (p=0.14)PsA statusABPA initial 2yearsABPA latter 2yearsControl initial 2yearsControl latter 2yearsfree9/255/2524/5031/50single9/2512/2521/5011/50intermittent7/255/255/505/50colonised03/2503/50PsA statusConclusion: Prolonged OCS use during treatment for ABPA did not increase PsA risk in the two years following ABPA diagnosis in CF children. ER -